Status | Study |
Active, not recruiting |
Study Name: Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Condition: Gastrinoma Glucagonoma Insulinoma Date: 2012-01-10 Interventions: Drug: capecitabine Given PO |
Recruiting |
Study Name: Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Condition: Pancreatic Alpha Cell Carcinoma Pancreatic Beta Islet Cell Carcinoma Date: 2011-10-04 Interventions: Drug: temozolomide Given PO |
Active, not recruiting |
Study Name: Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Condition: Pancreatic Gastrinoma Pancreatic Neuroendocrine Tumor G1 P Date: 2010-10-27 Interventions: Biological: Bevacizumab Given |
Active, not recruiting |
Study Name: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Condition: Adult Hepatocellular Carcinoma Advanced Adult Hepatocellular Carcinoma Date: 2009-11-06 Interventions: Biological: Bevacizumab Given |
Completed |
Study Name: A Study of IMC-A12 in Islet Cell Cancer Condition: Carcinoma Neuroendocrine Tumors Date: 2008-10-27 Interventions: Biological: IMC-A12 (cixutumumab) |
Terminated |
Study Name: A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors Condition: Carcinoma, Islet Cell Carcinoma, Pancreas Date: 2007-01-29 Interventions: Drug: sunitinib malate |
Completed |
Study Name: Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Condition: Islet Cell Carcinoma Neuroendocrine Carcinoma Date: 2006-08-02 Interventions: Drug: Everolimus 10 mg Partici |
Withdrawn |
Study Name: Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Condition: Gastrointestinal Carcinoid Tumor Islet Cell Carcinoma Date: 2005-09-26 Interventions: Drug: octreotide acetate Drug: vatalanib |
Completed |
Study Name: Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Condition: Gastrinoma Glucagonoma Insulinoma Date: 2005-08-16 Interventions: Drug: sorafenib tosylate 400 mg given orally Other N |
Completed |
Study Name: RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma Condition: Neuroendocrine Carcinoma Islet Cell Carcinoma Date: 2005-06-07 Interventions: Drug: RAD001 Starting dose of |